223418-63-1

Basic information

• Product Name: [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)-
• Synonyms: [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)-
• CAS NO: 223418-63-1
• Molecular Formula: C₁₄H₁₅N
• Molecular Weight: 197.2756
• Mol File: 223418-63-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)-(CAS DataBase Reference)
• NIST Chemistry Reference: [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)-(223418-63-1)
• EPA Substance Registry System: [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)-(223418-63-1)

Safety Data

• Hazardous Substances Data: 223418-63-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
[1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)is used as a key component in the synthesis of various drugs and medications. Its unique properties and biological activities contribute to the development of new treatments for a wide range of medical conditions.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In the field of organic chemistry, [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)is employed as a chiral auxiliary to facilitate the synthesis of enantiomerically pure compounds. This application is crucial for the production of pharmaceuticals, as the stereochemistry of a molecule can significantly impact its biological activity and efficacy.
Used as a Ligand in Organometallic Chemistry:
[1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)also serves as a ligand in organometallic chemistry, where it plays a vital role in the formation and stabilization of metal complexes. These complexes are essential in various catalytic reactions and can be used to develop new materials and technologies.
Further research and study of [1,1'-Biphenyl]-4-methanamine, .alpha.-methyl-, (.alpha.S)may lead to the discovery of new and innovative applications in the field of medicine and pharmaceuticals, potentially revolutionizing the way we approach the treatment of various medical conditions.

Upstream product

• 86217-82-5 1-(biphenyl-4-yl)ethanamine 
• 27298-97-1 (S)-1-(4-bromophenyl)ethylamine 
• 98-80-6 phenylboronic acid 

Relevant articles and documents

Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1

Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG) generating carbon dioxide and NADPH/NADH. Evidence suggests that the specific mutations in IDH1 are critical to the growth and reproduction of some tumor cells such as gliomas and acute myeloid leukemia, emerging as an attractive antitumor target. In order to discovery potent new mutant IDH1 inhibitors, we designed, synthesized and evaluated a series of allosteric mIDH1 inhibitors harboring the scaffold of 3-pyrazine-2-yl-oxazolidin-2-ones. All tested compounds effectively suppress the D-2-hydroxyglutarate (D-2-HG) production in cells transfected with IDH1-R132H and IDH1-R132C mutations at 10 μM and 50 μM. Importantly, compound 3g owns the similar inhibitory activity to the positive agent NI-1 and shows no significant toxicity at the two concentrations. The parallel artificial membrane permeation assay of the blood–brain barrier (PAMPA-BBB) identified 3g with a good ability to penetrate the blood–brain barrier (BBB). These findings indicate that 3g deserves further optimization as a lead compound for the treatment of patients with IDH1 mutated brain cancers.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.